804, 322 - 11 AVENUE SW, CALGARY, A0
Market cap: $83.8M (2/11/2026)
Price: $0.83
Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer
Announces Results of Special Meeting of Shareholders
Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics
Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer
Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O’Reilly, Dr. Neil Segal, and Dr. Van Morris
Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer
Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada
Provides Update on Special Meeting of Shareholders
Annual and Transition Report of Foreign Private Issuers
Prospectus Filed Pursuant to Rule 425
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Amended Registration Statement for Securities Issued in Business-Combination Transactions
Registration Statement for Securities Issued in Business-Combination Transactions
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
No filings found
Statement of Changes in Beneficial Ownership
Supplemental Filing
Appointment of Agent for Service of Process by Foreign Banks and Foreign Insurance Companies
Registration Statement for Securities of Certain Canadian Issuers